Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q2 2018 · 10-Q
Revenue$12.85K$12.85Kno prior Q2 2017 on file Net Income-$1.25M-$1.25MN/M vs Q2 2017 EPS Diluted$0.00$0.00−100.0% vs Q2 2017 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Operating Cash Flowderived-$741,610N/M Free Cash Flowderived-$741,610— Margins · derivedGross margin95.7%
Operating margin-6353.3%
Net margin-9731.1%
ended Jun 30, 2018 · filed Aug 13, 2018 · 44 d after period end